Emergence of colistin-resistant hypervirulent Klebsiella pneumoniae (CoR-HvKp) in China

Emerg Microbes Infect. 2022 Dec;11(1):648-661. doi: 10.1080/22221751.2022.2036078.

Abstract

Colistin is regarded as a last-resort agent to combat infections caused by multidrug-resistant (MDR) Gram-negative bacteria, especially carbapenem-resistant isolates. In recent years, reports of colistin-resistant Klebsiella pneumoniae (CoRKp) are increasing. However, the molecular mechanism and relevance of colistin resistance and virulence remain unclear. Fourteen CoRKp strains were retrospectively screened from 1884 clinical K. pneumoniae isolates during 2017-2018 in China. Six CoRKp strains belonging to ST11 were MDR strains. Plasmid-mediated mobile colistin-resistance genes had a low prevalence in CoRKp. Our results revealed that up-regulated expression of two-component systems, especially phoPQ, contributed more to colistin resistance. mgrB mutation was the most common molecular mechanism of colistin resistance, caused by either nonsense mutations or insertion sequences, which drove the overexpression of phoPQ system. This study also identified three novel point mutations in pmrAB system, in which D313N mutation in pmrB was proved to increase the MIC to colistin by 16-fold. In addition, 6 out of 14 CoRKP strains independently carried hypervirulence genes. All six strains showed medium-to-high virulence phenotype compared with NTUH-K2044 strain in mice intraperitoneal challenge models. We found that 4 strains were biofilm strong producers and transcriptome analysis revealed that three of them significantly up-regulated expression of type III fimbrial shaft gene mrkA. In conclusion, our result revealed the emergence of colistin-resistant and hypervirulent MDR K. pneumoniae, which is a noticeable superbug and could cause a severe challenge to public health.

Keywords: Klebsiella pneumoniae; ST11; colistin-resistance; hypervirulence; mgrB.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Proteins / genetics
  • Colistin / pharmacology
  • Drug Resistance, Bacterial / genetics
  • Klebsiella Infections* / microbiology
  • Klebsiella pneumoniae*
  • Mice
  • Microbial Sensitivity Tests
  • Retrospective Studies
  • beta-Lactamases / genetics

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • beta-Lactamases
  • Colistin

Grants and funding

This work was supported by National Natural Science Foundation of China: [Grant Number 82072318], National Key Research and Development Program of China [Grant Numbers 2021YFC2301000, 2021YFC2301002, and 2018YFE0101800], Beijing Key Clinical Specialty for Laboratory Medicine - Excellent Project [Grant Number ZK201000].